MÆDICA - a Journal of Clinical Medicine Logo
  • Home
  • Profile
  • Standards
    • Types of articles
    • Instructions for authors
    • Editing rules (peer-review protocol)
    • Official Journal’s protocols
  • Editorial Council
  • Peer-review TEAM
  • How to
  • Menu

Author archives

  • About
  • Latest Posts

Anca Mariana CIOBAN

Latest posts by Anca Mariana CIOBAN (see all)

  • Onset Risk Factors and Treatment Response Features of Refractory Hodgkin Lymphoma - July 2, 2015

Articles signed on MÆDICA, JCM:

Onset Risk Factors and Treatment Response Features of Refractory Hodgkin Lymphoma

SELECT ISSUE

MÆDICA - a Journal of Clinical Medicine | Vol. 8, nr. 4, 2013

CNCSIS - CMR - B+ OBBCSSR

HIGHLIGHTS

What is plagiarism

Plagiarism’s meaning comes from the Latin word ‘plagiarius,’ which means to kidnap. When someone uses the work of another writer or artist without properly citing the source or giving credit, that’s plagiarism. [...]

Committe on Publication Ethics

A forum for responsible and ethical research publishing – Code of Conduct and Best Practice Guidelines for Journal Editors.

Members Area


Onset Risk Factors and Treatment Response Features of Refractory Hodgkin Lymphoma

Oana STANCA, Anca Mariana CIOBAN, Anca Roxana LUPU, Cecilia GHIMICI, Irina TRIANTAFYLLIDIS, Andrei COLITA and Ileana Delia MUT

ABSTRACT

Background: The International Prognostic Factors Project on Advanced Hodgkin lymphoma (HL) developed a seven factor prognostic score consisting of gender, age, stage, serum albumin, hemoglobin, leukocytosis and lymphocytopenia for the newly diagnosed Hodgkin disease patients in advanced stages, who receive chemotherapy.

Objectives: The purpose of this study was to determine whether this prognostic score would also be useful for refractory Hodgkin lymphoma patients in monitoring response to treatment.

Material and method: In the period 2000-2012, we performed a study on a group of 91 patients to show that the prognostic factors identified by the International Prognostic Factors (IPF) score affect the event- free survival (EFS) and the overall survival (OS). Our study also intends to show that the results of these factors change with the treatment response in patients with HL included in the category of patients with refractory disease.

Results: B symptoms, onset lymph node, more than 3 areas involved, bulky disease, extranodal involvement, low serum albumin, erythrocytes sedimentation rate (ESR), C reactive protein (CRP), lactic dehydrogenase (LDH) and anemia were associated with poorer EFS and OS. Male gender, stage, histological type, age (>45 years) and leukocytosis were not associated with significantly poorer outcomes.

Conclusions: the prognostic score for advanced disease is also useful in predicting relapse in patients with HL and early detection of response in patients with refractory HL.

Keywords: Follicular lymphoma, diagnosis, prognosis

Full text | PDF



plic-mail[email protected]

 Terms and conditions

© MÆDICA - a Journal of Clinical Medicine - All rights reserved